Tennor Pharma Completes D+ Financing to Advance Late-Stage Clinical Trials of Core Assets

VCBeat has learned that TenNor Therapeutics (Suzhou) Co., Ltd. announced the completion of its Series D+ financing. Investors participating in the Series D+ round include Beijing Venture Capital and Borun Investment, while Yanchuang Capital, one of the lead investors in the Series D round, continued its support in the Series D+ round. This financing serves as an extension of the Series D round completed by TenNor Therapeutics in the first half of this year. The combined transaction value of the Series D and Series D+ rounds amounts to RMB 330 million. The funds raised will be used to advance late-stage clinical trials of TenNor Therapeutics’ core products.

TenNor Therapeutics is dedicated to the research and development of novel therapeutics for bacterial infections and metabolism-related diseases, leveraging its proprietary multi-target conjugate molecule technology platform and a global pipeline of drug candidates protected by intellectual property rights. Currently, three of TenNor Therapeutics’ drug candidates have entered Phase III clinical trials, targeting indications including Helicobacter pylori infection, implantable medical device-associated infections, and hepatic encephalopathy secondary to liver cirrhosis.

“We are delighted to have completed our D+ round of financing this year, building upon our Series D round. We sincerely thank all investors for their continued recognition and support of TenNor Therapeutics’ team and product pipeline,”Dr. Ma Zhenkun, Founder and CEO of TenNor Therapeuticsstated, “We will continue to adhere to our demand-driven and science-led new drug development strategy, accelerate the Phase III clinical trials of our core products, and strive to bring truly clinically valuable new drugs to patients as soon as possible.”

TenNor Therapeutics (Suzhou) Co., Ltd. is a clinical needs-driven company focused on the fields of bacterial infections and metabolism-related diseases, dedicated to developing first-in-class or best-in-class novel therapeutics for these indications. The company boasts a unique multi-target conjugate molecule drug discovery platform and a pipeline of novel drug products protected by global intellectual property rights. Currently, multiple candidates have advanced to late-stage clinical trials, targeting common and serious conditions such as Helicobacter pylori infection, implantable medical device-associated infections, hepatic encephalopathy in liver cirrhosis, and diarrhea-predominant irritable bowel syndrome (IBS-D). TenNor is committed to addressing unmet clinical needs in these areas and providing safe and effective novel therapies to patients in China and worldwide.

Beijing Innovation Industry Investment Co., Ltd., serving as a market-oriented innovation investment platform within the Beijing State-owned Assets Supervision and Administration system, fully leverages the advantages of its mixed-ownership structure. Spanning from sci-tech innovation investment to high-end, precision, and advanced industry investment, it incubates the industrialization of scientific and technological achievement transformation projects and guides the establishment of high-potential projects in Beijing. By capitalizing on its industry-finance empowerment services, it integrates the industrial resources of municipal state-owned enterprises (SOEs), supports their transformation and upgrading, and enhances the industrial ecosystem of municipal SOEs. It fosters the clustered development of Beijing’s high-end, precision, and advanced industries as well as specialized, refined, distinctive, and innovative (“Little Giant”) enterprises, thereby contributing to the construction of Beijing as a global science and technology innovation hub and facilitating the optimization and adjustment of the state-owned economy’s layout.

The lead investor in this round is Beijing Yuanjing Investment Fund, the first central-local collaborative technology transfer fund managed by Beijing Capital Ventures (BCV). Jointly supported by the Ministry of Science and Technology and the Beijing Science and Technology Innovation Fund, this private equity fund accelerates investment in technology transfer projects and original innovation initiatives. It primarily targets early- and growth-stage innovative technology enterprises possessing key core technologies, independent intellectual property rights, and capabilities in transferring technological achievements. The fund focuses on high-tech sectors aligned with national and Beijing municipal priority development strategies, including high-end equipment manufacturing, big data and next-generation information technology, and new energy.

Shanghai Borun Investment Management Co., Ltd. is headquartered in the Lujiazui Financial Center in Shanghai, specializing in private equity investment management with a focus on domestic and international equity investments. Upholding a firm belief in the long-term growth of China’s economy, Borun Equity Fund strategically invests in high-quality companies in emerging strategic sectors such as biopharmaceuticals and technological innovation. Complementing these investments with cross-border mergers and acquisitions and industry consolidation, the fund supports the growth of outstanding enterprises and cultivates leading players in niche markets, thereby delivering long-term, stable, and sustainable returns to investors.

“Yanchuang Capital,” fully named “Yanyuan Innovation Capital Group,” was founded in June 2010 as a private fund manager jointly established by Peking University alumni engaged in venture capital and the commercialization of university technological achievements. Adhering to value investment as its core philosophy, the company is committed to investing in strategic emerging industries and outstanding enterprises that have emerged during China’s historical trends of economic takeoff, technological catch-up, and industrial revitalization. Yanchuang Capital has long focused on two major investment sectors: advanced manufacturing and biopharmaceuticals. With assets under management exceeding RMB 6 billion, it has invested in more than 60 startups, 13 of which have gone public. In 2018, Yanchuang Capital began strategically allocating investments to the broader healthcare sector, including biopharmaceuticals. To date, it has invested in dozens of globally leading and domestically top-tier companies in innovative biologics, high-end medical devices, CROs, and CDMOs. Dedicated to leveraging rational capital to support the national innovation-driven development strategy, Yanchuang Capital aims to empower the high-quality development of the real economy and contribute to China’s efforts in achieving breakthroughs in key core technologies, attaining high-level scientific and technological self-reliance, and ensuring autonomous, secure, and controllable industrial supply chains.